Our study aimed to define whether a different molecular subset of GBM (especially in terms of IDH 1/2 mutation status, proliferation index, and MGMT promoter methylation) could result in a different fluorescence expression, possibly because of differences in metabolic pathways which could reflect a different genotype. The gene discussed is IDH1; the disease is glioblastoma.